Related Experiment Video
Updated: Jul 17, 2026

Assessment of Vascular Function in Patients With Chronic Kidney Disease
Published on: June 16, 2014
Role of nitric oxide-producing and -degrading pathways in coronary endothelial dysfunction in chronic kidney disease
Satoru Tatematsu1, Shu Wakino, Takeshi Kanda
1Department of Internal Medicine, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.
Insights
Chronic kidney disease (CKD) accelerates cardiovascular events by impairing coronary artery endothelial function. This dysfunction, linked to reduced nitric oxide (NO) pathways and elevated asymmetric dimethylarginine (ADMA), can be improved with all-trans retinoic acid therapy.
Area of Science:
- Cardiovascular Medicine
- Nephrology
- Endocrinology
Background:
- Cardiovascular events are common in chronic kidney disease (CKD).
- Endothelial dysfunction, linked to nitric oxide (NO) pathways and asymmetric dimethylarginine (ADMA), is implicated but not directly shown in coronary arteries in CKD.
- Investigating coronary endothelial function in early-stage CKD is crucial for understanding cardiovascular risk.
Purpose of the Study:
- To investigate coronary artery endothelial function in a canine model of CKD.
- To explore the role of NO pathways, ADMA, and related enzyme expression in CKD-induced coronary dysfunction.
- To evaluate the therapeutic potential of all-trans retinoic acid (ATRA) in restoring coronary function.
Main Methods:
- CKD was induced in dogs via heminephrectomy (1/2Nx) or five-sixths nephrectomy (5/6Nx).
- Coronary blood flow and arteriolar diameter responses to acetylcholine (endothelium-dependent) and sodium nitroprusside (endothelium-independent) were measured.
- Plasma ADMA, nitrite/nitrate levels, and coronary artery mRNA expression of DDAH-II and eNOS were analyzed. ATRA treatment was administered for 4 weeks.
Main Results:
- Renal ablation significantly reduced GFR and increased plasma ADMA levels.
- Acetylcholine-induced vasodilation was blunted in CKD groups, while sodium nitroprusside response remained unchanged.
- Plasma nitrite/nitrate decreased, and coronary DDAH-II and eNOS mRNA expression were downregulated in CKD. ATRA treatment improved vasodilation and restored eNOS expression.
Conclusions:
- Coronary endothelial function is impaired early in the course of CKD.
- This dysfunction is associated with downregulated eNOS and/or DDAH-II in coronary arteries.
- Targeting NO pathways, potentially with agents like ATRA, may prevent coronary dysfunction in CKD patients.
Abstract:
Cardiovascular events are accelerated in chronic kidney disease (CKD). Although deranged nitric oxide (NO) pathways and asymmetric dimethylarginine (ADMA) cause endothelial dysfunction, no direct evidence for coronary artery endothelial dysfunction in CKD has been documented. CKD was induced in male dogs by heminephrectomy (1/2Nx) or five-sixths nephrectomy (5/6Nx). After 4 wk, renal ablation reduced GFR (control 76 [54 to 85]; 1/2Nx 38 [29 to 47]; 5/6Nx 15 [12 to 46] ml/min) and elevated plasma ADMA (control 1.88 [1.68 to 2.54]; 1/2Nx 2.51 [2.11 to 3.55]; 5/6Nx 3.84 [2.16 to 3.95] micromol/L). Coronary circulatory responses to acetylcholine revealed marked increases in coronary blood flow in control group (83 +/- 17% increment) but blunted responses in 1/2Nx (34 +/- 8% increment) and 5/6Nx (20 +/- 4% increment). The acetylcholine-induced changes in epicardial arteriolar diameter, using needle-lens probe charge-coupled device videomicroscopy, showed similar results. The responsiveness to sodium nitroprusside did not differ among three groups. Plasma nitrite/nitrate levels decreased in 1/2Nx and 5/6Nx, and the mRNA expressions of dimethylarginine dimethylaminohydrolase-II (DDAH-II), ADMA-degrading enzyme, and endothelial NO synthase (eNOS) in coronary arteries were downregulated in 1/2Nx and 5/6Nx. Finally, 4-wk treatment with all-trans retinoic acid restored the impaired endothelium-dependent vasodilation and reversed the expression of eNOS but not DDAH-II. Coronary endothelial function is impaired in the early stage of CKD. The dysfunction is attributed to the downregulation of eNOS and/or DDAH-II in coronary arteries. Furthermore, the manipulation of NO pathways may constitute a therapeutic strategy for the prevention of coronary dysfunction in CKD.
More Related Videos
Related Concept Videos
Nitric Oxide Signaling Pathway
Coronary Artery Disease II: Pathophysiology
Chronic Kidney Disease I: Introduction
Chronic Kidney Disease III: Interprofessional Care
Acute Kidney Injury II: Pathophysiology
Hypertension II: Pathophysiology

